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RISKS AND OUTCOMES OF IDIOPATHIC PNEUMONIA SYNDROME 
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA- 
TION: THE INTENSITY OF THE CONDITIONING REGIMEN OUT- 
WEIGHS THE EFFECT OF ACUTE GRAFT-VERSUS-HOST DISEASE 
Fukuda, T.; Hack~mm, R.C.; Guthrie, K.A., Carter, R.A.; Sa;ld- 
maier, B.M.; Davis, C.; ~/lartin, P.ff.; &orb, R.F.; Madtes, D.K. 
Cli71ical Research DivisioT;, Fred Hittchil;soll Cancer Research Center, 
Seattle, f;I/~q. 
Background:Idiopathic pneumonia syndrome (IPS) is one of 
the major causes of mortality after allogeneic hematopoietic 
stem cell transplantation (HCT). Here, we investigated the 
incidence, risk factors and outcomes of IPS after myeloablative 
compared to nonmyeloablative allogeneic HCT. Methods:We 
retrospectively analyzed ata from patients who underwent 
allogeneic myeloablative (Conventional group; n=926) or non- 
myeloablative (NST group; n=183) HCT from related or 
unrelated onors at FHCRC between 12/1997 and 12/2001. 
IPS was diagnosed uring the first 120 days after transplant, 
based on NHLBI criteria including 1) multilobar infiltrates 
identified by CXR or CT scan, 2) symptoms/signs of pnemno- 
nia and evidence of abnormal physiology, and 3) absence of 
active lower respiratory tract infection. Survival was defined as 
alive 30 days after hospital discharge. Results:Patient charac- 
teristics and clinical course after IPS of the 2 groups are sum- 
marized in the Table. Multivariate analysis demonstrated that 
NST was associated with a significantly decreased risk of IPS 
(HR 0.24, p-0.001), while age greater than 40 years and 
grades 3-4 acute GVHD were associated with significantly 
increased risks (HR 1.8, p=0.009 and HR 3.4, p=0.001, respec- 
tively). Survival of IPS patients to 30 days past discharge was 
25% after either NST or conventional HCT. IPS patients who 
required mechanical ventilation (n=50) had a 2% survival 
while patients who did not require mechanical ventilation 
(n=31) had a 61% survival (p=0.001). The presence of renal 
failure at IPS onset (serum creatinine ~2 mg/dl) was associated 
with an increased probability for death before or within 30 
days of hospital discharge (OR 14, p=0.023) in a multiple 
logistic regression model. Conclusion:Recipients of NST 
have a significantly decreased risk of IPS compared to those 
given myeloablative conditioning despite greater patient age 
and similar incidence of severe acute GVHD. These findings 
suggest hat lung damage from myeloablative conditioning 
plays a crucial role in the development of IPS after transplant 
and that acute GVHD alone is insufficient to cause IPS. IPS is 
associated with a high mortality rate despite aggressive support 
when mechanical ventilation is required or renal failure is 
present. 
Patienl Characteristics 
Median age (yeals) 
ac& c~wD ~,~,do~ 3 4 
incidence uffPS (days 0-120~ 
Median time to IPS onset after transpkmt 
tdaym 
Mechanical ventilaOon (MV) required 
Median time to MV after IPS (days) (n=501 
Survival to 30 days afteJ hospital discharge 
Median time to deaO1 after IPS (days) (n=701 
Conventional (n=926) NST 1n=183) i p-value 
40 53 <0001 
27% 21% n.s. 
8.3gt 2,2% 0.002 
ConvenlionaI (n=77) NST (n=~l) 
22(range4 106) 16(.rage7-34) ; 
62% 50q~ 
! 
' (range 0 57) 2 (range 0-3) I 
25% 25% 
] 14(range 1-9791 15 (range 4-2791 
8 
TRAFFICKING OF EX VIVO EXPANDED DONOR DERIVED DENDRITIC 
CELLS AFTER ALLOGENEIC BMT 
Schi'mmelpfemfig, C.HJ; Tinnier, I.fI.2; Schulz, S.4; 3/lcBT"ide, J.M.2; 
Baker, ft.;; Fathmm;, C.G.2; Contag, C.H.S; Negrin, R.S. l 1. Stmzford 
U~liversity 3/ledical Cemel, Dpt. of MecliciJTe, Div. of BMT, Stallford, 
CA; 2. Dpt. of 3/ledici~ze, Div. of bnmunology and Rhemnatology, Stan- 
ford, CA; 3. Dpt. of Pediatrics, Div. of Neonatal mid Developme~;tal 
Medicitze, Sra~rd, CA; 4. Dpt. of Microbiology and bnm, unology, Div. 
of lt#ctious Diseases, Stal;ford, CA. 
Introduction: Little is known about survival and trafficking of ex 
vivo expanded DCs after adoptive transfer in animals. We investi- 
gated the trafficking patterns of allogeneie DCs transduced to 
express green fluorescence protein (gfp) and luciferase (iue) 
(gfp/luc + DCs) in mice that had received allogeneic BMT. Meth- 
ods: C57BL/6 BM was depleted of B220 ÷, CD3 + and GR-I + cells 
and was expanded for 7 days with GM-CSF, IL-4 and FIt3L. A 
retroviral vector encoding luc and gfp was used for transduction. 
Gfp/luc ÷ DCs were analyzed by FACS and injected i.v. at 4x106 
Des per animal into BALB/c mice that had received either allo- 
geneic myeloabiative BMT (BALB/c-mbl, n=5) or non-myeloabla- 
tive (BALB/e-n/mbl, n=5) BMT of C57BL/6 BM donor mice 10 
weeks prior. The hz vivo trafficking of the gfp/luc+DCs was moni- 
tored by biolmninescent imaging (BLI). Tissues were examined 
for gfp+ DCs using immunohistoehemistry. Results: Expanded 
C57BL/6 DCs expressed CD80, CD86 and MHC II. After trans- 
duction, CD 1 lc + gfp/Iuc + cells represented 20-27 % of viable cells. 
After injection , gfp/luc ÷ DCs were detectable in BALB/c-mbl and 
BALB/c-n/mbl mice over the entire observation period (BALB/c- 
mbl: 45d, BALB/c-n/mbh 101d). Immediately after injection, a 
high biolmninescent signal (BLS) was detected in the puhnonat y 
area. In BALB/c-mbl this signal decreased constantly until dl0, 
while in the BALB/c-n/mbl the BLS decreased on d2 and 
remained stable until d23. In both groups on d2 and d7 BLSs were 
detected in the area of liver and spleen. Starting on dl0 in 
BALB/c-mbl and on d23 in the BALB/c-n/mbl there was an 
increase of the BLS reaching amaximum in BALB/c-mbl on d35 
and in BALB/c-n/mbl on d77. The increase of the BLS was seen 
in both groups in the area of the gut, the spleen and the thymus. 
These findings were confirmed by immunohistochemistry of gut 
and spleen sections which showed gfp+CDllc +DCs. During the 
observation period no animal exhibited signs of GvHD. Conclu- 
sion: Here, we show that donor-derived, exvivo expanded gfp/luc + 
DCs survive in hosts after allogeneic BMT. They nfigrate to thy- 
mus, spleen and gut, but mice develop no clinical signs of GVHD. 
The ability to visualize DC survival and trafficking in an allogene- 
ic BMT setting will aid in the optimization of DC based treatment 
strategies. 
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IMPROVING OUTCOMES OF HAPLOIDENTICAL TRANSPLANTS FOR 
ACUTE LEUKEMIA 
Aversa, F.;; Terenzi, .4.1; Balkwti, S.1; Felici;~i, RJ; Carotti, 4.1; Fal- 
ciTzelli, F J; Tabilio, A J; Falzetti, F.z; Velardi, A J; &mtucci, A J; Reis- 
he15 I7.21 Martelli, AI.F. 1 1. Hematology, Perztgia, Perltgia, Italy; 
2. ~Veizmann Imtitute, Rehovot, Israel. 
Our first report on 36 acute leukemia p tients howed a mega- 
dose of T-depleted HSC is crucial factor in promoting engraft- 
ment across the HLA barriers. Modifications to our approach 
have led to remarkable progress. In 1995 fludarabine replaced 
cyclophosphamide in our TBI-based conditioning regimen and we 
started to select he CD34+ cells using the Ceprate system (44 
patients). In 1999, we changed to the CliniMacs device and sus- 
pended post transplant G-CSF (65 patients). Population included 
145 patients (age range: 2 - 62 years), 76 AML and 69 ALL, at 
high-risk of relapse because of disease status at transplant (27 bad- 
risk CR I, 48 CR &#61619; II, 70 in relapse). Disease status was 
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the major risk factor for relapse in 69 ALL patients (0.89 and 0.59 
for those transplanted in relapse and in CR &#61619; II, respec- 
tively; 0.00 in CR i). Lack of an NK-cell alloreactive donor was 
the major risk factor for relapse in 76 AIML patients (0.12 for 
recipients of NK-alloreactive donors vs 0.68 for the others). In the 
109 patients who received the fludarabine-modified conditioning 
regimen and immunoselected CD34+ cells primary engraftment 
improved fi'om the 80% of our original series of 36 patients to the 
current 94%. Incidence of severe GvHD dropped from 18% to 
7%. 65/109 patients received fludarabine in the conditioning, 
Clinimacs-selected CD34+ cells and no G-CSF post-transplant. 
Immune recovery improved. The clinical impact was most marked 
in AML patients transplanted in a W remission. The probability of 
infection-related mortality was 0.18 in these 26 patients vs 0.70 in 
15 patients at the same stage of disease who received Ceprate- 
treated grafts and G-CSF post-transplant. 38/65 patients were 
transplanted in remission and the 3 year probability of EFS is 0.60 
and 0.40 for the 19 AML and 19 ALl,, respectively. 
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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PRIMARY 
SYSTEMIC AMYLOIDOSIS (AL): THE IMPACT OF SELECTION CRITERIA 
ON OUTCOME 
3/[ollee, P.; ~'Vechaleka1", A.; Pereira, D.; Franke, N.; Reece, D.; 
Che~, C.; Stewa:'t, A. Princess Margaret Hospital, To*'o*~to, ON, 
Gmada. 
Introduction: ASCT has produced higher response rates than 
conventional chemotherapy in patients (pts) with AL. However, 
transplant-related mortality (TRM) remains high and reported 
series are subject o selection bias. Methods: We report a retro- 
spective analysis of all pts with symptomatic AL referred to onr 
center from '96-'01, identifying prognostic variables and the 
impact of ASCT in the entire population. Results: 48 pts had pri- 
mary AL: median age 58 yrs; median time from diagnosis to refer- 
ral 1.Smonths; and prior therapy in 27%. Organ involvement: 
renal 68%; cardiac 77%; liver 42%; and neurologic 19%. The 26 
pts who were deemed ASCT candidates were younger (55 vs 63 
yrs, p=0.001), had a better performance status (96% vs 73% with 
ECOG score -<2, p=0.02) and a trend to a better left ventricular 
ejection traction (27% vs 45% with EF <50%, p=0.2) and less syn- 
cope (4% vs 18%, p=0.11). Five pts died during the peri collec- 
tion period from progressive disease oi- mobilization complica- 
tions and one failed to mobilize stem cells. 20 pts underwent 
ASCT following high-dose melphalan. TRM was 35%; however, 
since Jan'99 TRM has fallen from 50% to 20%. Intent-to-treat 
organ responses were: renal 46%, cardiac 25% and liver 50%. 
The 3yr OS post-ASCT was 56% with improved outcome pre- 
dicted by a better performance status (p=0.08), normal ALP 
(p=0.08), nephrotic syndrome (p=0.0l) and absence of severe 
hypotension (3yr OS 0% vs 75% for systolic BP<vs>90mmItg, 
p<0.001). The 3yrOS for all 48 referred pts (i.e.whether t ans- 
planted or not) was 44%, and this was not significantly" better for 
transplant candidates. Improved outcomes for all referred pts were 
associated with good ECOG performance status (<2 vs >2, 
p=0.001), the presence of nephr'otic syndrome (p=0.06), no 
increase in septal wall thickness (p=0.07) and a systolic 
BP>90mmHg (p<0.001). Conclusions: Selection of appropriate 
candidates for transplantation f primary AL is important and can 
resnlt in avoidance of excessive TRM. Those with systolic 
BP_<90mmHg and poor performance status (ECOG >2) have an 
exceedingly high mortality and should not be transplanted. For 
those undergoing ASCT, organ response rates appear promising, 
but overall only small numbers benefit. Conclusive evidence of 
improved survival for this select group of pts is still lacking and 
will require randomized trials. 
GRAFT PROCESSING 
II 
HIGH INCIDENCE OF EPSTEIN-BARR VIRUS LYMPHOPROLIFERATIVE 
DISEASE (EBV-LPD) AFTER CD34-SELECTED AUTOLOGOUS PERIPH- 
ERAL BLOOD STEM CELL TRANSPLANT (PBSCT) IN CHILDREN WITH 
NEUROBLASTOMA(NB) 
Gr~:pp, S. ~; Powell, ff.~; Gr!(fin, G.~; Callahan, C.1, Aplenc, R. ~, B:mi~, 
N.J. j 1. C,~ildreT~s Hospital, Philadelphia, PA; 2. AI Dupont, ~l/7lm- 
kagton, DE. 
EBV-LPD is a disorder anging from a polyclonal B-cell lym- 
phoproliferation to lyn~phoma. It occurs as a result of inmmno- 
suppression and after allogeneic BMT, especially in recipients of 
T cell depleted grafts. EBV-LPD after autologous transplant is
uncommon. We describe an unnsually high incidence of EBV- 
LPD in children undergoing tandem high dose chemotherapy 
supported with CD34 selected peripheral blood stem cells 
(CD34+PBSC). 156 patients were treated on one of two sinfilar 
tandem PBSCT protocols, CHP-594 or CHP-667 at 4 institu- 
tions over a period of 6 years. Both studies employ 5 cycle induc- 
tion therapy, followed by tandem autologons PBSCT. 28 pts were 
enrolled on CHP-667 and 128 on CHP-594, including 119 chil- 
dren with NB, 29 with Ewing sarcoma nd 8 with other sarcomas. 
108/156 patients received CD34+PBSC, with 48 receiving unse- 
lected PBSC. CD34 selection was performed with 2 devices: 
Ceprate (n=26) and Isolex (n=82). Average dose of CD34 selected 
cells infused to patients on CHP-594 was 7xl06/kg; average dose 
on CHP-667 was 8.7x106/kg. CD34+PBSC were given in 81/128 
CHP-594 patients; 27/28 patients on CHP-667 received 
CD34+PBSC. Five patients developed EBV-LPD for an overall 
incidence of 3.2%. Incidence on the two studies was 1.6% on 
CHP-594 and 10.7% in the limited number of patients on CHP- 
667 (p=.041). Median time to develop EBV-LPD after transplant 
was 3 months (range 1-5 months). All patients who contracted 
LPD were in the CD34 selected group and all had NB (p=NS). 
4/5 patients experienced a CR of their LPD to rituximab therapy; 
3/5 are cnrrently living (1 having died from LPD and 1 from NB), 
and are 28, 13, and 4 months post therapy for EBV LPD. We 
conclude that the incidence of EBV-LPD after this highly 
immunosuppressive tandem autologous PBSCT regimen is higher 
than expected. Tandem transplant is itself highly immunosuppres- 
sive. However, as all patients with LPD had received 
CD34+PBSC processed on the Nexell device, CD34 selection also 
may play a role in the development of EBV-LPD. The risk of con- 
comitant T cell depletion with CD34+PBSC in autologous 
PBSCT regimens must be carefully examined and balanced 
against he potential benefit of umor cell purging, or stem ceil 
engineering strategies must include a plan to retnrn T cells as well. 
12 
OPTIMAL USE OF PERIPHERAL CD34 COUNTS (PCD34) TO GUIDE 
LEUKAPHERESIS IN AUTOLOGOUS PERIPHERAL HEMATOPOIETIC 
STEM CELL TRANSPLANTATION (PHSCT) 
Griffins, D.L., Kiss, J.E.; Stam'zak, H.M.; Koch, E.K.; Yeager, A.M.; 
Dom~enhevg, A.D. Medich~e, University of Pittshm'gh, Pittsbm'gh, PA. 
The ability to monitor PCD34 counts has the potential to gmide 
PHSCT collection after mobilization. Attempting to collect stem 
ceils when mobilization is insufficient is expensive and results in 
unnecessary isk and inconvenience for the patient. We measured 
PCD34 counts in a series of 123 recipients of autologous PHSCT. 
Absolute CD34 count was measured using Beckman-Coulter 
StemKit, modified to determine CD34 viability by 7-aminoactino- 
mycin-D exclusion (Donnenberg et al, Cytotherapy 2002). Test 
,result urnover was approximately 70 minutes fro m sample acces- 
sion to reporting. In the present test se , the decision to collect 
was based solely on WBC performed aily following mobilization 
(G-CSF +/- chemo). Patients reported *'or leukapheresis and 
CD34 testing when their WBC was greater than or equal to 2, 
500 cells/microliter. Patients who did not reach their collection 
goal (2-5 x 10E6 CD34/kg) after the initial leukapheresis were 
called back for additional leukaphereses (up to 4). To determine 
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